Research map: Safety of Flecainide and Propafenone in Patients With Atrial Fibrillation and Structural Heart Disease

Back to the article

Papers in this map

  1. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews · Matthew James Page · 2021 · 106363 citations · Cited by this paper
  2. Mediastinal Air Entrapment During Extravascular ICD Implantation: A Preventable Cause of Elevated Shock Impedance · 2026 · Related
  3. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) · Gerhard Hindricks · 2020 · 10158 citations · Cited by this paper
  4. Temporal Coagulation Biomarker Profiles After Andexanet Alfa Use for Procedure‐Related Cardiac Tamponade · 2026 · Related
  5. Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or Placebo · Debra S. Echt · 1991 · 3274 citations · Cited by this paper
  6. Subclinical Venous Injury in Transvenous Lead Extraction: Histological Correlation With Clinical Risk Factors · 2026 · Related
  7. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) · Isabelle C. Van Gelder · 2024 · 2934 citations · Cited by this paper
  8. Refining Residual Ischemic Stroke Risk in Anticoagulated Atrial Fibrillation Using Index Outpatient LA Diameter: The CHA 2 DS 2 ‐VALa Score · 2026 · Related
  9. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation · Craig T. January · 2019 · 2224 citations · Cited by this paper
  10. Detection of Accessory Pathway Recurrence at Standard and Abbreviated Waiting Periods and Implications for Recurrence Following Pediatric Radiofrequency Ablation · 2026 · Related
  11. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation · Paulus F. Kirchhof · 2020 · 2202 citations · Cited by this paper
  12. Apparent Unmasking of Left Anterior Fascicular Ventricular Tachycardia After Prior Left Posterior Fascicular Ablation: Possible Alternative Exit From a Shared Septal Purkinje Substrate · 2026 · Related
  13. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation · José A. Joglar · 2023 · 892 citations · Cited by this paper
  14. Influence of High‐Frequency Low‐Tidal Volume Versus Jet Ventilation on Acute and Long‐Term Outcomes Following Pulmonary Vein Isolation · 2026 · Related
  15. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? · Subramaniam Krishnan · 1993 · 242 citations · Cited by this paper
  16. Clinical Outcomes of Different Stroke Prevention Strategies in Patients With Inadvertent Left Atrial Appendage Electrical Isolation · 2026 · Related
  17. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation · Lucie Valembois · 2019 · 214 citations · Cited by this paper
  18. Impact of Pulse Field Ablation on Hemolysis Markers: A Single‐Center Experience · 2026 · Related
  19. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation · E Aliot · 2010 · 168 citations · Cited by this paper
  20. Association of Diagnostic Code Priority With Identification of True Cardiac Arrest in Patients Presenting to the Emergency Department · 2026 · Related
  21. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). · Jeffrey L. Anderson · 1994 · 89 citations · Cited by this paper
  22. Safety and efficacy of long-term sodium channel blocker therapy for early rhythm control: the EAST-AFNET 4 trial · Andreas Rillig · 2024 · 41 citations · Cited by this paper
  23. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease · Tyson S. Burnham · 2021 · 30 citations · Cited by this paper
  24. Use of Flecainide in Stable Coronary Artery Disease: An Analysis of Its Safety in Both Nonobstructive and Obstructive Coronary Artery Disease · Hasan Ashraf · 2021 · 23 citations · Cited by this paper
  25. Propafenone use in coronary artery disease patients undergoing atrial fibrillation ablation · Serkan Çay · 2022 · 13 citations · Cited by this paper
  26. Flecainide in structural heart diseases: A contemporary reappraisal beyond the CAST · Davide Genovese · 2025 · 8 citations · Cited by this paper
  27. Rationale and Design of a Randomized Controlled Clinical Trial on the Safety and Efficacy of Flecainide versus Amiodarone in the Cardioversion of Atrial Fibrillation at the Emergency Department in Patients with Coronary Artery Disease (FLECA-ED) · Panagiotis Tsioufis · 2023 · 6 citations · Cited by this paper
  28. Propafenone‐ vs . amiodarone‐associated adverse cardiac outcomes in patients with atrial fibrillation and heart failure · Yi Lin · 2025 · 4 citations · Cited by this paper
  29. Is it safe to use class 1C antiarrhythmic drugs in patients with coronary artery disease and/or cardiomyopathy? · Peter G. Pantlin · 2025 · 3 citations · Cited by this paper
  30. Class Ic antiarrhythmic therapy after PCI in new-onset atrial fibrillation: Safety and clinical outcomes from a nationwide cohort · Ting‐Chun Huang · 2026 · 2 citations · Cited by this paper
  31. 952 SAFETY OF CLASS IC ANTIARRHYTHMIC DRUGS IN CORONARY ARTERY DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS · Darío Turturiello · 2022 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)